´ëÇÑ°£¾ÏÇÐȸ (¿Â¶óÀÎ) 1st KLCA Live Webinar - Navigating the First-Line Systemic Treatment Options for Advanced HCC : 2021-08-27±³À°ÀÏÀÚ : 2021-08-27
±³À°Àå¼Ò : ¿Â¶óÀÎ
±³À°ÁÖÁ¦ :
(¿Â¶óÀÎ) 1st KLCA Live Webinar - Navigating the First-Line Systemic Treatment Options for Advanced HCCÁÖÃÖ±â°ü : ´ëÇÑ°£¾ÏÇÐȸ
´ã´çÀÚ : ÀÌÁøÈ Â÷Àå
¿¬¶ôó : 02-373-1005
À̸ÞÀÏ :
klca@hbni.co.kr ±³À°Á¾·ù : ³»°ú, ¿Ü°ú, ¿µ»óÀÇÇаú, ¹æ»ç¼±Á¾¾çÇаú, º´¸®°ú
Âü¼®¿¹»óÀοø : 200¸í
Èñ¸ÁÆòÁ¡ : 3Á¡
Áö¿ª :
ºÎ»ê±¤¿ª½Ã±³À°½Ã°£ : 3 ½Ã°£ 0ºÐ
¼¼ºÎ¼ö°·á : 0¿ø
ºñ°í
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 08-27 ¿Â¶óÀο¬¼ö±³À°(½Ç½Ã°£È»ó°ÀÇ) 18:05~18:40 Sorafenib with hepatic arterial chemotherapy in advanced HCC ¹é¾çÇö(µ¿¾Æ´ëÇб³º´¿ø)
±³À°½Ã°£ 08-27 ¿Â¶óÀο¬¼ö±³À°(½Ç½Ã°£È»ó°ÀÇ) 18:40~19:15 Sequential treatment of sorafenib/nivolumab and combined local therapy in HCC patient with lung metastasis Çã³»À±(ÀÎÁ¦´ëÇб³ ÇØ¿î´ë¹éº´¿ø)
±³À°½Ã°£ 08-27 ¿Â¶óÀο¬¼ö±³À°(½Ç½Ã°£È»ó°ÀÇ) 19:15~19:50 Partial response in advanced HCC treated with lenvatinib as 1st line therapy ¼±¤ÀÏ(°í½Å´ëÇб³ º¹À½º´¿ø)
±³À°½Ã°£ 08-27 ¿Â¶óÀο¬¼ö±³À°(½Ç½Ã°£È»ó°ÀÇ) 19:50~20:25 Atezolizumab and bevacizumab combination therapy in HCC patient with multiple metastasis Ȳ»ó¿¬(µ¿³²±Ç¿øÀÚ·ÂÀÇÇпø)
±³À°½Ã°£ 08-27 ¿Â¶óÀο¬¼ö±³À°(½Ç½Ã°£È»ó°ÀÇ) 20:25~21:05 Navigating the First-Line Systemic Treatment Options for Advanced Hcc ÀüÈ«Àç(Â÷ÀÇ°úÇдëÇб³ ºÐ´çÂ÷º´¿ø)